Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lamivudine + nevirapine + stavudine or lamivudine + nevirapine + zidovudine
- Development stage
- Unknown
- Lead developer
- Peking Union Medical College
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This entry refers to two distinct first-line antiretroviral therapy (ART) regimens evaluated in a clinical study by Peking Union Medical College for the treatment of HIV/AIDS in Chinese patients. The first regimen consists of lamivudine (3TC), nevirapine (NVP), and stavudine (d4T), while the second consists of lamivudine, nevirapine, and zidovudine (AZT). Both regimens utilize a combination of two nucleoside reverse transcriptase inhibitors (NRTIs) and one non-nucleoside reverse transcriptase inhibitor (NNRTI) to inhibit HIV-1 reverse transcriptase, thereby preventing viral replication. These generic regimens were studied to optimize treatment guidelines for resource-limited areas in China, focusing on efficacy, safety, and immune reconstitution.
- Other names
- 3TC + NVP + d4T3TC + NVP + AZTfirst line ARV (3TC+NVP+D4T or 3TC+NVP+AZT)
02
Targets
Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on lamivudine + nevirapine + stavudine or lamivudine + nevirapine + zidovudine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lamivudine + nevirapine + stavudine or lamivudine + nevirapine + zidovudine.